PCRX vs PEAK
Pacira BioSciences, Inc. (PCRX) versus PEAK (PEAK) — a side-by-side from cached financials, not a winner call.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
PEAK (PEAK) common stock.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
PEAK does not have a complete income-statement cache yet.
PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
Not investment advice. Open the PCRX and PEAK stock pages for the full models.
Not investment advice.